Get the Stockscreener App
3.39
0.59%
-0.02
Pre-market:
3.36
-0.03
-0.88%
Revance Therapeutics Inc stock is traded at $3.39, with a volume of 2.37M.
It is down -0.59% in the last 24 hours and up +11.88% over the past month.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
See More
Previous Close:
$3.41
Open:
$3.45
24h Volume:
2.37M
Relative Volume:
0.90
Market Cap:
$353.88M
Revenue:
$234.04M
Net Income/Loss:
$-323.92M
P/E Ratio:
-0.8921
EPS:
-3.8
Net Cash Flow:
$-223.46M
1W Performance:
+10.78%
1M Performance:
+11.88%
6M Performance:
+17.30%
1Y Performance:
-51.78%
1-Day Range:
$3.3505
$3.495
1-Week Range:
$3.05
$3.61
52-Week Range:
$2.30
$7.56
Revance Therapeutics Inc Stock (RVNC) Company Profile
Name
Revance Therapeutics Inc
Sector
Industry
Phone
(615) 724-7755
Address
1222 DEMONBREUN STREET, NASHVILLE, CA
Compare RVNC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
3.39 | 353.88M | 234.04M | -323.92M | -223.46M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Downgrade | Mizuho | Buy → Neutral |
| Jan-09-24 | Downgrade | Goldman | Buy → Neutral |
| Aug-16-23 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-22-22 | Initiated | Goldman | Buy |
| Oct-25-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-15-20 | Reiterated | Needham | Buy |
| Aug-11-20 | Resumed | Mizuho | Buy |
| Mar-23-20 | Downgrade | Goldman | Buy → Neutral |
| Dec-02-19 | Initiated | Goldman | Buy |
| Oct-30-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Feb-15-19 | Initiated | Wells Fargo | Market Perform |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
| Nov-16-18 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-17-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Apr-20-18 | Reiterated | Mizuho | Buy |
| Mar-27-18 | Initiated | Needham | Buy |
| Mar-05-18 | Initiated | Goldman | Buy |
| Jan-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-06-17 | Initiated | Guggenheim | Buy |
| Dec-06-17 | Reiterated | Mizuho | Buy |
| Nov-27-17 | Initiated | Barclays | Overweight |
| Nov-17-17 | Initiated | Mizuho | Buy |
| Aug-22-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Revance Therapeutics Inc Stock (RVNC) Latest News
Kirby McInerney LLP Reminds Revance Therapeutics, Inc. - GlobeNewswire
Kirby McInerney LLP Reminds Revance Therapeutics, Inc. (RVNC) Investors of Class Action Filing and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Revance Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your RightsRVNC - Morningstar
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance LawsuitRVNC - Marketscreener.com
Class Action Filed Against Revance Therapeutics, Inc. - GlobeNewswire
Revance Therapeutics jumps after Teoxane offers $3.60 a share - MSN
Revance gains as it plans to enter talks with Teoxane on likely superior bid - MSN
Revance to Hold Talks With Teoxane on Takeover Proposal - MarketWatch
Revance gains as it plans to enter talks with Teoxane on likely superior bid (RVNC:NASDAQ) - Seeking Alpha
REVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Revance Therapeutics, Inc. Class Action Lawsuit - PR Newswire
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action - Business Wire
Biotech Co. Revance Faces Suit After Tender Offer Weakens - Law360
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Teoxane Outbids Crown With New Revance Therapeutics Bid - Law360
Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class Action - Marketscreener.com
Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs - MSN
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Teoxane makes cash offer to buy Revance Therapeutics By Investing.com - Investing.com Canada
Revance Therapeutics Shares Rise as Teoxane Looks to Upend Crown Deal - MarketWatch
Revance Therapeutics jumps after Teoxane offers $3.60 a share (NASDAQ:RVNC) - Seeking Alpha
Teoxane makes cash offer to buy Revance Therapeutics - Investing.com
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash - Yahoo Finance
Teoxane S.A. submitted a proposal to acquire all remaining stake in Revance Therapeutics, Inc. for $360 million. - Marketscreener.com
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Revance Therapeutics (RVNC) Investors with Losses to Contact Firm’s Attorneys Before Feb. 8th Deadline in Securities Fraud Action - AccessWire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
HAGENS BERMAN, NATIONAL TRIAL ATTOREYS, Encourages Revance Therapeutics (RVNC) Investors with Significant Losses to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations - AccessWire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Short Interest Down 23.1% in December - MarketBeat
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Given New $3.00 Price Target at Barclays - MarketBeat
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Franklin Resources Inc. - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
Revance Therapeutics ticks higher as holder says Crown deal undervalues company - MSN
HighTower Advisors LLC Lowers Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Wellington Management Group LLP Invests $2.32 Million in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc.RVNC - Business Wire
Revance Therapeutics' SWOT analysis: tender offer shakes up specialty pharma stock - Investing.com
725,000 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Acquired by Oddo BHF Asset Management Sas - MarketBeat
Revance receives acquisition offer from Crown Laboratories for $3.10 per share - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - Kilgore News Herald
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Marketscreener.com
Crown Laboratories Commences Friendly Tender Offer for All Outst - GuruFocus.com
Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share - Marketscreener.com
Kirkland Advises Crown Laboratories on Amended Merger Agreement with Revance - Legal Desire News Network
Crown Labs announces merger with Revance Therapeutics - Johnson City Press
Revance Therapeutics' SWOT analysis: crown's tender offer lifts stock outlook By Investing.com - Investing.com Nigeria
Revance Therapeutics Inc Stock (RVNC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):